Phase II Trial Opens: Telehealth tDCS Plus Mindfulness vs Sham for Cannabis Use Disorder — What Clinicians Need to Know

References

1. 1.NYU Langone Health. (2024). Telehealth-delivered tDCS for cannabis addiction recovery: The C.A.R.E.S. initiative. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07184983
2. 2.Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., Jung, J., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., & Grant, B. F. (2015). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry, 72(12), 1235-1242. https://doi.org/10.1001/jamapsychiatry.2015.1858
3. 3.Boggio, P. S., Sultani, N., Fecteau, S., Merabet, L., Mecca, T., Pascual-Leone, A., Basaglia, A., & Fregni, F. (2008). Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: A double-blind, sham-controlled study. Drug and Alcohol Dependence, 92(1-3), 55-60. https://doi.org/10.1016/j.drugalcdep.2007.06.011
4. 4.Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L. (2016). Psychosocial interventions for cannabis use disorder. Cochrane Database of Systematic Reviews, 5, CD005336. https://doi.org/10.1002/14651858.CD005336.pub4
5. 5.Chandra, S., Radwan, M. M., Majumdar, C. G., Church, J. C., Freeman, T. P., & ElSohly, M. A. (2019). New trends in cannabis potency in USA and Europe during the last decade (2008-2017). European Archives of Psychiatry and Clinical Neuroscience, 269(1), 5-15. https://doi.org/10.1007/s00406-019-00983-5